Optimum-02 virtually replicates Optimum-01, and $IDYA heads for US filing. Via @APEXONCo -> https://t.co/y6X9Hs5kKf
@omphalos007 @avidresearch That probably makes an $IMCR vs $IDYA comparison on PFS alone slightly unfair.
@avidresearch Kimmtrak is weird - nice OS benefit, hardly anything on PFS. I can't recall why at this point $IMCR $IDYA
$IDYA PFS curves from Optimum-02 https://t.co/h4ZYytTrsc
Let's remember again that $NVS dumped off darovasertib for $2.5m in cash + $3.5m in $IDYA series B preferred stock.
$IDYA darovasertib data from registrational Optimum-02 trial in uveal melanoma are out. What to look for: https://t.co/1LQa0X6xJa
This is getting quite tiresome: first $ORIC, now $ALLO & $IDYA. Why are you sitting on market-sensitive data rather than releasing it now? https://t.co/N8q95re7ho
Who won #ESMO25 and who lost? Via @ApexOnco https://t.co/EWzHIIH1Ck $IOBT $CELC $RCUS $CGEM $IDYA $NUVL $AGEN $GILD $DSNKY $INCY $CATX $LPTX $OLMA $SMMT $AVBP $GMAB $EXEL $CGEN $ZLAB $RHHBY
Novel synthetic lethality approaches from Synnovation, Artios & $NVS leave much to prove. Via @ApexOnco at #ESMO25 -> https://t.co/B5FWHlomX6 $IDYA $RPTX $GSK
@jeromeleonard5 @NotthatkindofDr At #Jefferies24 $IDYA said data were expected at a medical conf in 2025, if I recall.
@jeromeleonard5 @NotthatkindofDr GSK4418959 / IDE275? I was kind of hoping to see FIH data on that at #ESMO25 $GSK $IDYA
